immPRINT

The Problem​

About 1 in 400 individuals is affected by an undiagnosed primary immunodeficiency (PID), often experiencing preventable complications such as recurrent infections, increased postoperative morbidity, and intolerance to radiotherapy. This high level of underdiagnosis reflects the absence of a simple, reliable diagnostic assay. Identification still relies largely on clinical history and practitioner experience. Among the most serious and costly consequences of PID is an increased susceptibility to infections. Patients are at particularly high risk of, for example, impaired wound healing following surgery with higher complication rates. Early identification of these vulnerable individuals is critical, as it enables access to treatments that can significantly improve both life expectancy and quality of life.

The Solution​

immPRINT is a simple, high-accuracy solution for identifying immunodeficiency, achieving 99% accuracy from a single tube of blood. A first-in-class approach, that integrates a straightforward pipeline designed for easy implementation within existing clinical workflows. By enabling reliable PID detection, immPRINT supports more precise patient stratification, helping improved clinical trial selection or clinically actionable applications, e.g. early identification of post-surgical complications.

Looking for​

Collaborators and non-dilutive funding

Information on the technology

immPRINT is also available as technology asset

News and background